China has been hit by another medical scandal after 29 children were given the wrong vaccine in the city of Shijiazhuang in Hebei province.
A nurse at the Huitong community health service centre, has been detained for allegedly giving the children Haemophilus b conjugate vaccine Act-HIB as a pentavalent vaccine, or 5-in-1 vaccine, for personal gain, the provincial government said.
The price of the pentavalent vaccine is reportedly 600 yuan ($89) while that of Act-HIB vaccine is about 100 yuan.
The Qiaoxi health authority has cancelled the business license of the Huitong community health service centre and doctor's license of the centre's head.
Local authorities will give the 29 children the right vaccine, the Global Times quoted a government statement as saying.
Taking Act-HIB as the pentavalent vaccine will not harm the children's health, the Qiaoxi health authority announced last week, one day after a local woman revealed the case on Sina Weibo, which sparked public attention.
Two local health officials were also removed in the matter, according to the Global Times.
The case is the latest vaccine issue which has sparked public concern in China since the Changchun Changsheng incident.
Changchun Changsheng Biotechnology, one of China's biggest vaccine makers, produced 252,600 sub-standard human rabies vaccine and fake production records in July 2018.
The revelation triggered a massive public outcry.
More than 80 officials were removed or charged for the incident, the China Central Television reported.
--IANS
gsh/ksk
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
